Synnovation Therapeutics develops small molecule therapies targeting validated cancer pathways, utilizing advanced medicinal chemistry to optimize pharmacological profiles. The company aims to enhance treatment outcomes for cancer patients by advancing a diverse pipeline of precision medicine candidates into clinical trials.
Funding
$139M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are driven by specific, validated molecular pathways, but existing therapies often lack optimal pharmacological profiles, leading to suboptimal treatment outcomes. There is a need for precision medicine approaches that can more effectively target these pathways with best-in-class small molecule therapeutics.
Solution
Synnovation Therapeutics is developing a pipeline of small molecule therapies designed to precisely target validated cancer pathways. By leveraging expertise in cancer biology and medicinal chemistry, Synnovation optimizes the pharmacological profiles of its drug candidates to achieve best-in-class efficacy and safety. The company's mission is to advance these novel agents into clinical trials, with the goal of transforming cancer care through patient-focused precision medicine. Their lead program, SNV4818, is a pan-mutant-selective PI3Kα inhibitor currently in Phase 1 trials for the treatment of solid tumors.
Target Audience
The primary target audience includes cancer patients, oncologists, and clinical researchers seeking more effective and targeted treatment options.
Features
- Focus on small molecule therapies for targeted cancer treatment
- Medicinal chemistry approach to optimize drug pharmacology
- Pipeline of novel agents targeting validated cancer pathways
- SNV4818: a pan-mutant-selective PI3Kα inhibitor in Phase 1 trials